1,101
Views
6
CrossRef citations to date
0
Altmetric
Clinical Study

Plasma heparanase is associated with blood glucose levels but not urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage

, , , , , & show all
Pages 698-701 | Received 03 May 2017, Accepted 29 May 2017, Published online: 10 Oct 2017

References

  • Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164–176.
  • American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37(Suppl. 1):S14–S80.
  • Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev. 2008;4:39–45.
  • Wada T, Shimizu M, Toyama T, et al. Clinical impact of albuminuria in diabetic nephropathy. Clin Exp Nephrol. 2012;16:96–101.
  • Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int. 2008;74:22–36.
  • Toblli JE, Bevione P, Di Gennaro F, et al. Understanding the mechanisms of proteinuria: therapeutic implications. Int J Nephrol. 2012;2012:546039.
  • Nasser NJ. Heparanase involvement in physiology and disease. Cell Mol Life Sci. 2008;65:1706–1715.
  • Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest. 2001;108:341–347.
  • Levy-Adam F, Feld S, Suss-Toby E, et al. Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PLoS One. 2008;3:e2319.
  • Morita H, Yoshimura A, Inui K, et al. Heparan sulfate of perlecan is involved in glomerular filtration. J Am Soc Nephrol. 2005;16:1703–1710.
  • Morita H, Yoshimura A, Kimata K. The role of heparan sulfate in the glomerular basement membrane. Kidney Int. 2008;73:247–248.
  • van den Hoven MJ, Rops AL, Vlodavsky I, et al. Heparanase in glomerular diseases. Kidney Int. 2007;72:543–548.
  • Katz A, Van-Dijk DJ, Aingorn H, et al. Involvement of human heparanase in the pathogenesis of diabetic nephropathy. Isr Med Assoc J. 2002;4:996–1002.
  • Lewis EJ, Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin. Diabetes Care. 2008;31:S202–S207.
  • Maxhimer JB, Somenek M, Rao G, et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes. 2005;54:2172–2178.
  • Han J, Woytowich AE, Mandal AK, et al. Heparanase upregulation in high glucose-treated endothelial cells is prevented by insulin and heparin. Exp Biol Med. 2007;232:927–934.
  • An XF, Zhou L, Jiang PJ, et al. Advanced glycation end-products induce heparanase expression in endothelial cells by the receptor for advanced glycation end products and through activation of the FOXO4 transcription factor. Mol Cell Biochem. 2011;354:47–55.
  • Qin Q, Niu J, Wang Z, et al. Heparanase induced by advanced glycation end products (AGEs) promotes macrophage migration involving RAGE and PI3K/AKT pathway. Cardiovasc Diabetol. 2013;12:37.
  • van den Hoven MJ, Rops AL, Bakker MA, et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int. 2006;70:2100–2108.
  • Shafat I, Ilan N, Zoabi S, et al. Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels. PLoS One. 2011;6:e17312.
  • Shafat I, Agbaria A, Boaz M, et al. Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function. PLoS One. 2012;7:e44076.
  • Yu JY, An XF, Liu JS, et al. Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage. Diabetes Res Clin Pract. 2010;87:157–160.
  • Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci. 2000;25:349–351.
  • Wijnhoven TJ, van den Hoven MJ, Ding H, et al. Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy. Diabetologia. 2008;51:372–382.
  • Gil N, Goldberg R, Neuman T, et al. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes. 2012;61:208–216.
  • Goldberg R, Rubinstein AM, Gil N, et al. Role of heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy. Diabetes. 2014;63:4302–4313.